







# Retrospective Analysis of Demographic and Clinical Factors Associated with Etiology of Febrile Respiratory Illness among US Military Basic Trainees

Damaris S Padin
Dennis Faix
Stephanie Brodine
Hector Lemus
Anthony Hawksworth
Shannon Putnam
Patrick Blair



# Naval Health Research Center

# Report No. 13-01

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. Approved for public release: distribution is unlimited.

This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research.

Naval Health Research Center P.O. BOX 85122 San Diego, California 92186-5122



# **RESEARCH ARTICLE**

**Open Access** 

# Retrospective analysis of demographic and clinical factors associated with etiology of febrile respiratory illness among US military basic trainees

Damaris S Padin<sup>1\*</sup>, Dennis Faix<sup>1</sup>, Stephanie Brodine<sup>2</sup>, Hector Lemus<sup>2</sup>, Anthony Hawksworth<sup>1</sup>, Shannon Putnam<sup>1</sup> and Patrick Blair<sup>1</sup>

#### **Abstract**

**Background:** Basic trainees in the US military have historically been vulnerable to respiratory infections. Adenovirus and influenza are the most common etiological agents responsible for febrile respiratory illness (FRI) among trainees and present with similar clinical signs and symptoms. Identifying demographic and clinical factors associated with the primary viral pathogens causing FRI epidemics among trainees will help improve differential diagnosis and allow for appropriate distribution of antiviral medications. The objective of this study was to determine what demographic and clinical factors are associated with influenza and adenovirus among military trainees.

Methods: Specimens were systematically collected from military trainees meeting FRI case definition (fever ≥38.0°C with either cough or sore throat; or provider-diagnosed pneumonia) at eight basic training centers in the USA. PCR and/or cell culture testing for respiratory pathogens were performed on specimens. Interviewer-administered questionnaires collected information on patient demographic and clinical factors. Polychotomous logistic regression was employed to assess the association between these factors and FRI outcome categories: laboratory-confirmed adenovirus, influenza, or other FRI. Sensitivity, specificity, positive and negative predictive value were calculated for individual predictors and clinical combinations of predictors.

**Results:** Among 21,570 FRI cases sampled between 2004 and 2009, 63.6% were laboratory-confirmed adenovirus cases and 6.6% were laboratory-confirmed influenza cases. Subjects were predominantly young men (86.8% men; mean age  $20.8 \pm 3.8$  years) from Fort Jackson (18.8%), Great Lakes (17.1%), Fort Leonard Wood (16.3%), Marine Corps Recruit Depot (MCRD) San Diego (19.0%), Fort Benning (13.3%), Lackland (7.5%), MCRD Parris Island (8.7%), and Cape May (3.2%). The best multivariate predictors of adenovirus were the combination of sore throat (odds ratio [OR], 2.94; 95% confidence interval [CI], 2.66–3.25), cough (OR, 2.33; 95% CI, 2.11–2.57), and fever (OR, 2.07; 95% CI, 1.90–2.26) with a PPV of 77% (p  $\leq$  .05). A combination of cough, fever, training week 0–2 and acute onset were most predictive of influenza (PPV =38%; p  $\leq$  .05).

**Conclusions:** Specific demographic and clinical factors were associated with laboratory-confirmed influenza and adenovirus among military trainees. Findings from this study can guide clinicians in the diagnosis and treatment of military trainees presenting with FRI.

Keywords: Adenovirus, Influenza, Military trainees, Military medicine, Diagnosis

Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: dspadin@gmail.com

<sup>&</sup>lt;sup>1</sup>Naval Health Research Center, 140 Sylvester Road, San Diego, CA 92106,

### **Background**

Historically, military basic trainees have been vulnerable to severe epidemics of febrile respiratory illness (FRI) [1,2]. Several factors predispose military trainees to the spread respiratory infections, including crowded living conditions and stressful work environments. The epidemiology and pathogens causing FRI among military trainees is unique and differs from the civilian setting [3]. Training populations are primarily prone to outbreaks caused by adenovirus and influenza, which often co-circulate and present with similar clinical signs and symptoms [4].

In the presence of an epidemic, it is generally acceptable to make a reasonable diagnosis based on clinical signs and symptoms until laboratory confirmation can be obtained. It is still debatable whether specific demographic and clinical symptoms can be used to distinguish among respiratory pathogens. A few studies have identified clinical predictors for influenza in civilian and military populations [5-9]. However, few studies have focused on other respiratory pathogens like adenovirus that have caused substantial morbidity among military trainees [10,11].

Adenovirus infections have caused significant morbidity among US military trainees since the virus was discovered in the 1950s. With interrupted training schedules, high morbidity, and the occasional death, it has proved to be costly to the US Government [12,13]. Live oral vaccines against types 4 and 7 adenovirus were developed in the late 1960s and were successful in reducing FRI rates and adenoviral morbidity after their introduction in 1971. However, the sole vaccine manufacturer stopped production in 1996, and adenovirus returned to US recruit training centers and commands (RTCs) at pre-vaccine levels after vaccine supplies were depleted in 1999. The clinical presentation of adenovirus-associated FRI has been described as more severe than non-adenovirus-associated FRI, particularly when it is a novel strain in which there is little to no immunity [14]. Adenoviruses cases present with higher temperatures and have an increased number of cases with a cough and sore throat compared with non-adenovirus-associated FRI cases [14].

FRI infections present with a wide range of clinical features. Identifying demographic and clinical factors associated with the primary viral pathogens causing FRI epidemics among military trainees will help improve differential diagnosis, allow for appropriate distribution of antiviral medications, and ultimately improve troop readiness. The objective of this study was to determine what demographic and clinical factors are associated with influenza and adenovirus among military trainees at RTCs in an effort to aid clinical diagnosis when laboratory confirmation is not available.

#### **Methods**

#### Study population

Since 1996, the Naval Health Research Center (NHRC) has conducted ongoing laboratory-based surveillance FRI at eight basic training centers across the United States: Fort Benning Army Training Center, Georgia; Fort Jackson Army Training Center, South Carolina; Fort Leonard Wood Army Training Center, Missouri; Lackland Air Force Base, Texas; Great Lakes Naval Training Command, Illinois; Marine Corps Recruit Depots (MCRDs) San Diego, California, and Parris Island, South Carolina; and Cape May Coast Guard Training Center, New Jersey. Length of basic training varies throughout branches of military service: 10 weeks for the Army, 7 weeks Navy, 8 weeks Air Force, 12 weeks Marine Corps, and 8 weeks Coast Guard. In support of surveillance, military basic trainees from these training sites meeting case definition for FRI (fever ≥38.0°C with either cough or sore throat; or provider-diagnosed pneumonia) were recruited for the study. All subjects provided informed consent. This study was approved by the Naval Health Research Center (NHRC) Institutional Review Board (protocol NHRC.1999.0002).

#### Specimen and data collection

Throat and nasal swabs and clinical data were systematically collected from consenting US military trainees meeting the case definition for FRI. Each training site except for Cape May had a trained research assistant dedicated to enrolling subjects in the study and collecting clinical specimens. Sampling of a maximum ranging from 10 to 20 recruits per site per week was performed. Subjects were systematically selected from trainees presenting to their local clinic meeting FRI case definition. Trainees were tracked throughout the entirety of their training, with the exception of MCRD San Diego where trainees left for Camp Pendleton for weeks 4 through 7 of training. Trainees awaiting the start of training were assigned to training week 0.

Questionnaires administered by research assistants (corpsmen at Cape May) collected information on patient demographic and clinical factors, including age, sex, number of days since symptoms began, number of visits to sick call during illness, diagnosis of pneumonia, history of asthma, smoking history (pack-years), history of influenza vaccination, week of training, and experience of any of the following symptoms during his or her current illness: sore throat, cough, shortness of breath, nasal congestion, headache, conjunctivitis, body aches, and nausea or vomiting. The patient's oral temperature was abstracted from the medical record or taken by the research assistant. Medical records were reviewed to abstract data needed for questionnaire.

#### Specimen processing

Up to two throat and/or nasal swabs were collected by on-site personnel using Dacron respiratory swabs (MicroTest viral transport media (VTM), Remel, Inc., Lenexa, KS, USA). Swabs were immediately placed into the VTM and broken off so that the tip remained in the media. VTM were maintained on ice or refrigerated at 4°C (2–8°C) during processing and stored within 60 minutes at –70°C. Specimens were stored locally at –70°C until shipped on dry ice to NHRC for viral culture and molecular diagnostic processing. Shipping occurred on a weekly or biweekly basis (not to exceed 1 month) depending on season and FRI rates at respective training sites. The NHRC laboratory is accredited by the College of American Pathologists.

Upon arrival at NHRC, all specimens underwent molecular testing (polymerase chain reaction [PCR]) for a number of respiratory pathogens, including adenovirus and influenza A. Viral culture was performed on 20% of randomly selected specimens that were PCR positive for adenovirus and on all of the specimens that were PCR negative for adenovirus. Viral culture was performed using two different cell lines: primary monkey kidney cell line (either rhesus or cynomolgus) for influenza and an A549 cell line for adenovirus. Influenza-positive isolates were typed using hemagglutination inhibition, and adenovirus isolates were typed using microneutralization techniques [15,16]. Viral culture was used to test for influenza A and B and other FRI pathogens (respiratory syncytial virus, and parainfluenza viruses 1 and 3).

#### Data handling

The main outcome variables were laboratory-confirmed influenza or adenovirus, defined as having any specimen positive for influenza or adenovirus using PCR or culture. Adenovirus and influenza A results were determined by PCR or culture, and influenza B was determined by culture alone. The main outcome variable was categorized into a three-level variable based on FRI laboratory determination: adenovirus positive, influenza positive, or other FRI (negative for adenovirus and influenza). Categorical variables were constructed from continuous clinical variables based on clinical definitions. Acute onset was defined as ≤3 days since symptom onset. Fever was defined as temperature ≥38.0°C. Those who were afebrile were enrolled as provider-diagnosed pneumonia cases. Assuming influenza vaccine protection takes 14 days to develop, the influenza-vaccinated group was defined as those vaccinated longer than 14 days prior to testing. Data from the 2009 H1N1 pandemic were included in the analysis.

#### Statistical analysis

Statistical analysis was performed using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). Frequencies

and descriptive statistics were performed. Mean and standard deviation were reported for normally distributed variables, and median and range were reported for non-normally distributed variables. A multivariate polychotomous logistic regression model was developed to model the probability of laboratory-confirmed adenovirus, laboratory-confirmed influenza, and other FRI against clinical and demographic predictors (age, sex, acute onset, fever, pneumonia diagnosis, sore throat, cough, shortness of breath, nasal congestion, headache, conjunctivitis, body aches, nausea/vomiting, asthma, smoking history, influenza vaccination status, training week, and enrollment site). Colinearity diagnostics were done to assess confounding between predictor variables. First clinic visit and cigarette pack-years were not incorporated in the model because of the possibility of collinearity with acute onset and smoking.

Manual stepwise model-building strategy was used to develop the model that included all variables significantly associated with the main outcome variables. Predictors were included in the model one at a time and removed if not significant at p <0.05. Asthma was the only predictor that fell out of the model. Parameter estimates and significance levels were reviewed during model building to assess the relative importance of each variable. Adjusted odds ratios (ORs) and confidence intervals (CIs) were reported for each multivariate logistic regression model. Variance inflation factor and tolerance values were evaluated to assess multicollinearity and model fitness. All variables were considered statistically significant at p <0.05.

Variables demonstrating associations with laboratory-confirmed adenovirus and influenza (ie, the predictors of influenza and adenovirus) in the reduced multivariate model were incorporated into various clinical combinations. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for individual predictors and various clinical combinations of predictors in an effort to model these as clinical diagnostic tests. Binomial proportions with 95% CIs were calculated.

### **Results**

# Descriptive analysis

Among 21,570 FRI cases sampled between November 2004 and October 2009, 63.6% were laboratory-confirmed adenovirus cases and 6.7% were laboratory-confirmed influenza cases. Trainees presented to the clinic 3 days after self-reported onset of symptoms (range 1-90). For 68.0% of trainees, it was their first illness-related clinic visit. Subjects were predominantly young men (86.8% men; mean years  $20.8 \pm 3.8$ ) from Fort Jackson (18.8%), Great Lakes (17.1%), Fort Leonard Wood (16.3%), MCRD San

Table 1 Demographic and clinical characteristics of military trainees according to etiology of febrile respiratory illness (2004–2009)

Age (years)         208 (3.8)         205 (3.7)         21.2 (3.7)         21.2 (4.2)           Sympton duration (days)         3.0 (1.90)         3.0	Variable by FRI outcome	Total study population	Adenovirus	Influenza	Other
Age (years)         208 (38)         20.5 (3.7)         21.2 (4.7)         21.2 (4.7)           Symptom duration (days)         3.0 (1.90)         3.0 (1.90)         20 (1.52)         3.0 (8.8)           Frempenature (***)         3.2 (1.5)         3.8 4 (1.5)         3.8 4 (1.3)         3.8 2 (1.5)           Days since vaccination* (Influenza)         1.0 (0.99)         1.0 (0.79)         1.0 (0.77)         0.5 (0.40)           Days since vaccination* (Influenza)         3.10 (0.365)         3.30 (0.363)         10.0 (0.351)         2.90 (0.365)           Tailing week         4.7 (3.0)         5.0 (2.6)         2.2 (2.3)         4.7 (3.0)           Tailing season         ***		(n = 21,570)	( <i>n</i> = 13,725)	(n = 1,435)	(n = 6,410)
Symptom duration (days)         3.0 (1-90)         3.0 (1-90)         3.0 (1-52)         3.0 (1-84)           Temperature (**C)         38.7 (1.5)         38.4 (1.5)         38.4 (1.3)         38.7 (1.5)           Smoking history (pack-years)         1.0 (0-99)         1.0 (0-99)         1.0 (0-763)         10.0 (0-763)         29.0 (0-365)           Taining week         4.7 (3.0)         5.0 (2.6)         3.2 (3.7)         4.7 (3.8)           Categorical variables**         n (%)         n (%)         n (%)         n (%)           Taining season         Training season         4.675 (21.7)         3.144 (22.9)         78 (5.4)         1.438 (22.4)           Spring         4.675 (21.7)         3.144 (22.9)         78 (5.4)         1.438 (22.4)           Spring         4.675 (21.7)         3.144 (22.9)         72 (50.7)         1.849 (28.8)           Sex         Female         2.846 (13.2)         2.657 (19.4)         72.7 (50.7)         1.849 (28.8)           Sex         Female         2.846 (13.2)         1.508 (11.4)         257 (17.6)         1.070 (61.60)           Make         1.8724 (86.8)         12.157 (88.6)         1.183 (82.4)         5.384 (18.4)           Actual conset         2.23 (3.4)         1.20 (44.5)         3.75 (26.1)         2	Continuous variables <sup>e</sup>	value <sup>a</sup>	value <sup>a</sup>	value <sup>a</sup>	value <sup>a</sup>
Temperature (*C)	Age (years)	20.8 (3.8)	20.5 (3.7)	21.2 (3.7)	21.2 (4.2)
Smoking history (pack-years)         1.0 (0-99)         1.0 (0-72)         0.5 (0-40)           Days since vaccination* (influenza)         310 (0-363)         330 (0-363)         100 (0-31)         290 (0-36)           Training week         4 / (30)         50 (2-6)         3.2 (3.2)         4 / (38)           Categorical variables*         n (%)         n (%)         n (%)         n (%)         n (%)           Training season         161         5,088 (23.6)         3.423 (24.9)         227 (15.8)         1,438 (22.4)           Spring         4,57 (30.5)         4,501 (32.8)         403 (28.1)         1,670 (26.1)           Winter         5,233 (24.3)         2,657 (19.4)         727 (50.7)         1,849 (28.8)           Sex         18 (14)         252 (17.6)         1,060 (76.1)         1,849 (28.8)           Sex         18 (14)         252 (17.6)         1,026 (16.0)         1,038 (16.0)         1,383 (82.4)         5,384 (84.0)           Acute corset         23 days         1,275 (86.8)         12,157 (86.0)         1,183 (82.4)         5,384 (84.0)           Fewer         23 days         1,275 (89.1)         7,623 (55.5)         1,060 (73.9)         4,070 (73.9)           4 23 days         1,275 (89.1)         7,623 (55.2)         1,060 (73.9	Symptom duration (days)	3.0 (1–90)	3.0 (1–90)	3.0 (1–52)	3.0 (1-84)
Days since vaccination (** (Influenza))         31.0 (0-365)         33.0 (0-363)         10.0 (0-351)         29.0 (0-365)           Training week         47 (3.0)         5.0 (2.6)         3.2 (3.2)         4.7 (3.8)           Categorical variables*         n (%)	Temperature (°C)	38.2 (1.5)	38.4 (1.5)	38.4 (1.3)	38.2 (1.5)
Training week 4,7 (3.0)	Smoking history (pack-years)	1.0 (0–99)	1.0 (0–99)	1.0 (0-72)	0.5 (0-40)
Categorical variables®         n (%)         n (%	Days since vaccination <sup>b</sup> (Influenza)	31.0 (0–365)	33.0 (0–363)	10.0 (0–351)	29.0 (0–365)
Training season  Fall \$0.88 (23.6) \$3.423 (24.9) \$27 (15.8) \$1.438 (22.4) \$5pring \$4.675 (21.7) \$3.144 (22.9) \$78 (5.4) \$1.453 (22.7) \$1.580 (4.75 (21.7) \$1.440 (22.9) \$78 (5.4) \$1.453 (22.7) \$1.580 (4.75 (20.5) \$1.540 (23.8) \$1.670 (26.1)	Training week	4.7 (3.0)	5.0 (2.6)	3.2 (3.2)	4.7 (3.8)
Fail S,088 (23.6) 3,423 (24.9) 227 (15.8) 1,438 (22.4) Spring 4,675 (21.7) 3,144 (22.9) 78 (5.4) 1,533 (22.7) Summer 6,574 (30.5) 4,501 (32.8) 403 (28.1) 1,670 (26.1) Winter 5,233 (24.3) 2,657 (19.4) 727 (50.7) 1,849 (28.8) Sex  Female 2,846 (13.2) 1,568 (11.4) 252 (17.6) 1,026 (16.0) Male 18,724 (86.8) 12,157 (88.6) 1,183 (82.4) 5,384 (84.0) Acute onset	Categorical variables <sup>e</sup>	n (%)	n (%)	n (%)	n (%)
Spring         4,675 (21.7)         3,144 (22.9)         78 (5.4)         1,453 (22.7)           Summer         6,574 (30.5)         4,501 (32.8)         403 (28.1)         1,670 (26.1)           Winter         5,233 (24.3)         2,657 (19.4)         727 (50.7)         1,849 (28.8)           Sex         Female         2,846 (13.2)         1,568 (11.4)         252 (17.6)         1,026 (16.0)           Male         18,724 (86.8)         12,157 (88.6)         1,183 (82.4)         5,384 (84.0)           Acute onset         ±3 days         12,750 (59.1)         7,623 (55.5)         1,060 (73.9)         4,067 (63.4)           >3 days         8,802 (40.9)         6,102 (44.5)         3.75 (26.1)         2,343 (36.6)           Fever         288.0°C         17,917 (83.0)         11,780 (13.0)         12,232 (85.9)         4,740 (73.9)           < 28.0°C	Training season				
Summer       6,574 (30.5)       4,501 (32.8)       403 (28.1)       1,670 (26.1)         Winter       5,233 (24.3)       2,657 (19.4)       727 (50.7)       1,849 (28.8)         Sex         Female       2,846 (13.2)       1,568 (11.4)       252 (17.6)       1,026 (16.0)         Male       18,724 (86.8)       12,157 (88.6)       1,183 (82.4)       5,384 (84.0)         Acute onset       23 days       12,750 (59.1)       7,623 (55.5)       1,060 (73.9)       4,067 (63.4)         ≥3 days       8,820 (40.9)       6,102 (44.5)       375 (26.1)       2,343 (36.6)         Fever       288.0°C       17,917 (83.0)       11,945 (87.0)       1,232 (85.9)       4,740 (73.9)         ≤38.0°C       3,653 (17.0)       1,780 (13.0)       1,212 (85.9)       4,740 (73.9)         ≤48.0°C       3,653 (17.0)       1,780 (13.0)       1,065 (74.2)       4,727 (73.7)         No       6,911 (32.0)       8,867 (64.6)       1,065 (74.2)       4,727 (73.7)         No       6,911 (32.0)       8,867 (84.6)       10.7 (7.5)       1,151 (18.0)         No       1,868 (86.6)       12,101 (88.1)       107 (7.5)       1,151 (18.0)         No       1,868 (86.6)       12,211 (88.1)       107 (7.5)       1,151 (1	Fall	5,088 (23.6)	3,423 (24.9)	227 (15.8)	1,438 (22.4)
Winter         5,233 (24.3)         2,657 (19.4)         727 (50.7)         1,849 (28.8)           Sex           Female         2,846 (13.2)         1,568 (11.4)         252 (17.6)         1,026 (16.0)           Male         18,724 (86.8)         12,157 (88.6)         1,183 (82.4)         5,384 (94.0)           Acute onset         32 days         12,750 (59.1)         7,623 (55.5)         1,060 (73.9)         4,067 (63.4)           ≥ 3 days         8,820 (40.9)         6,102 (44.5)         375 (26.1)         2,343 (36.6)           Fever           ≥ 38.0°C         17,917 (83.0)         11,945 (87.0)         1,232 (85.9)         4,740 (73.9)           ≤ 38.0°C         17,917 (83.0)         1,780 (13.0)         20.3 (11.1)         1,670 (26.1)           First visit         4         7	Spring	4,675 (21.7)	3,144 (22.9)	78 (5.4)	1,453 (22.7)
Sex         Female         2,846 (13.2)         1,568 (11.4)         252 (17.6)         1,026 (16.0)           Male         18,724 (86.8)         12,157 (88.6)         1,183 (82.4)         5,384 (84.0)           Acute onset         ≤3 days         12,750 (59.1)         7,623 (55.5)         1,060 (73.9)         4,067 (63.4)           >3 days         8,820 (40.9)         6,102 (44.5)         375 (26.1)         2,343 (36.6)           Fever         ≥38.0°C         17,917 (83.0)         11,945 (87.0)         1,232 (85.9)         4,740 (73.9)           <38.0°C	Summer	6,574 (30.5)	4,501 (32.8)	403 (28.1)	1,670 (26.1)
Female       2,846 (13.2)       1,568 (11.4)       252 (17.6)       1,026 (16.0)         Male       18,724 (86.8)       12,157 (88.6)       1,183 (82.4)       5,384 (84.0)         Acute onset       Sadays       12,750 (59.1)       7,623 (55.5)       1,060 (73.9)       4,067 (63.4)         > 3 days       8,820 (40.9)       6,102 (44.5)       375 (26.1)       2,343 (36.6)         Fever       \$38.0°C       17,917 (83.0)       11,945 (87.0)       1,232 (85.9)       4,740 (73.9)         4,380°C       3,653 (17.0)       1,780 (13.0)       203 (14.1)       1,670 (26.1)         First visit       Yes       14,659 (68.0)       8,867 (64.6)       1,065 (74.2)       4,727 (73.7)         No       6,911 (32.0)       4,858 (35.4)       370 (25.8)       1,683 (26.2)         Pneumonia*       Yes       2,882 (13.4)       1,624 (11.8)       107 (7.5)       1,151 (18.0)         No       1,868 (86.6)       12,101 (88.1)       13,228 (92.5)       5,259 (82.0)         Sore throat       Yes       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,775 (18.3)         Cough       2,249 (89.2)       12,559 (91.5)<	Winter	5,233 (24.3)	2,657 (19.4)	727 (50.7)	1,849 (28.8)
Male       18,724 (86.8)       12,157 (88.6)       1,183 (82.4)       5,384 (84.0)         Acute onset       ≤3 days       12,750 (59.1)       7,623 (55.5)       1,060 (73.9)       4,067 (63.4)         >3 days       8,820 (40.9)       6,102 (44.5)       375 (26.1)       2,343 (36.6)         Fever       238.0°C       17,917 (83.0)       11,945 (87.0)       1,232 (85.9)       4,740 (73.9)         <38.0°C	Sex				
Acute onset  ≤3 days 12,750 (59.1) 7,623 (55.5) 1,060 (73.9) 4,067 (63.4) >3 days 8,820 (40.9) 6,102 (44.5) 375 (26.1) 2,343 (36.6)  Fever  ≥38.0°C 17,917 (83.0) 11,945 (87.0) 1,232 (85.9) 4,740 (73.9) <38.0°C 3,653 (17.0) 1,780 (13.0) 203 (14.1) 1,670 (26.1)  First visit  Yes 14,659 (68.0) 8,867 (64.6) 1,065 (74.2) 4,727 (73.7) No 6,911 (32.0) 4,858 (35.4) 370 (25.8) 1,683 (26.2)  Pneumonia <sup>c</sup> Yes 2,882 (13.4) 1,624 (11.8) 107 (7.5) 1,151 (18.0) No 18,688 (86.6) 12,101 (88.1) 1,328 (92.5) 5,259 (82.0)  Sore throat  Yes 19,174 (88.9) 12,771 (93.0) 1,168 (81.3) 5,235 (81.7) No 2,396 (11.1) 954 (7.0) 267 (18.6) 1,175 (18.3)  Cough  Yes 19,249 (89.2) 12,559 (91.5) 1,410 (98.3) 5,280 (82.4) No 3,321 (10.7) 1,166 (8.5) 5,170 1,130 (17.6)  Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8) No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  No 4328 (20.1) 1223 (81.8) 1153 (80.3) 4,866 (75.9) No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	Female	2,846 (13.2)	1,568 (11.4)	252 (17.6)	1,026 (16.0)
\$\begin{align*} \begin{align*} \begin{align*} \begin{align*} \begin* \begin{align*} \begin* \begin{align*} \begin* \b	Male	18,724 (86.8)	12,157 (88.6)	1,183 (82.4)	5,384 (84.0)
>3 days       8,820 (40.9)       6,102 (44.5)       375 (26.1)       2,343 (36.6)         Fever       ≥38.0°C       17,917 (83.0)       11,945 (87.0)       1,232 (85.9)       4,740 (73.9)         <38.0°C	Acute onset				
Fever	≤3 days	12,750 (59.1)	7,623 (55.5)	1,060 (73.9)	4,067 (63.4)
\$\begin{array}{cccccccccccccccccccccccccccccccccccc	>3 days	8,820 (40.9)	6,102 (44.5)	375 (26.1)	2,343 (36.6)
<38.0°C	Fever				
First visit  Yes 14,659 (68.0) 8,867 (64.6) 1,065 (74.2) 4,727 (73.7) No 6,911 (32.0) 4,858 (35.4) 370 (25.8) 1,683 (26.2)  Pneumonia <sup>c</sup> Yes 2,882 (13.4) 1,624 (11.8) 107 (7.5) 1,151 (18.0) No 18,688 (86.6) 12,101 (88.1) 1,328 (92.5) 5,259 (82.0)  Sore throat  Yes 19,174 (88.9) 12,771 (93.0) 1,168 (81.3) 5,235 (81.7) No 2,396 (11.1) 954 (7.0) 267 (18.6) 1,175 (18.3)  Cough  Yes 19,249 (89.2) 12,559 (91.5) 1,410 (98.3) 5,280 (82.4) No 2,321 (10.7) 1,166 (8.5) 25 (1.7) 1,130 (17.6)  Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8) No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9) No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)	≥38.0°C	17,917 (83.0)	11,945 (87.0)	1,232 (85.9)	4,740 (73.9)
Yes       14,659 (68.0)       8,867 (64.6)       1,065 (74.2)       4,727 (73.7)         No       6,911 (32.0)       4,858 (35.4)       370 (25.8)       1,683 (26.2)         Pneumonia <sup>c</sup> Yes       2,882 (13.4)       1,624 (11.8)       107 (7.5)       1,151 (18.0)         No       18,688 (86.6)       12,101 (88.1)       1,328 (92.5)       5,259 (82.0)         Sore throat         Yes       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough         Yes       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath         Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion       4328 (20.1)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)	<38.0°C	3,653 (17.0)	1,780 (13.0)	203 (14.1)	1,670 (26.1)
No       6,911 (32.0)       4,858 (35.4)       370 (25.8)       1,683 (26.2)         Pneumonia <sup>c</sup> Yes       2,882 (13.4)       1,624 (11.8)       107 (7.5)       1,151 (18.0)         No       18,688 (86.6)       12,101 (88.1)       1,328 (92.5)       5,259 (82.0)         Sore throat       7es       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough         Yes       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath         Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion       Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)	First visit				
Pneumonia <sup>c</sup> Yes       2,882 (13.4)       1,624 (11.8)       107 (7.5)       1,151 (18.0)         No       18,688 (86.6)       12,101 (88.1)       1,328 (92.5)       5,259 (82.0)         Sore throat       7es       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough       7es       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath         Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion         Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)         Headache	Yes	14,659 (68.0)	8,867 (64.6)	1,065 (74.2)	4,727 (73.7)
Yes       2,882 (13.4)       1,624 (11.8)       107 (7.5)       1,151 (18.0)         No       18,688 (86.6)       12,101 (88.1)       1,328 (92.5)       5,259 (82.0)         Sore throat       7es       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough       7es       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath         Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         No       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)         Headache	No	6,911 (32.0)	4,858 (35.4)	370 (25.8)	1,683 (26.2)
No       18,688 (86.6)       12,101 (88.1)       1,328 (92.5)       5,259 (82.0)         Sore throat       Yes       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough         Yes       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath         Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion         Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)	Pneumonia <sup>c</sup>				
Sore throat         Yes       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough       Yes       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath       Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion       Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)         Headache	Yes	2,882 (13.4)	1,624 (11.8)	107 (7.5)	1,151 (18.0)
Yes       19,174 (88.9)       12,771 (93.0)       1,168 (81.3)       5,235 (81.7)         No       2,396 (11.1)       954 (7.0)       267 (18.6)       1,175 (18.3)         Cough       Yes       19,249 (89.2)       12,559 (91.5)       1,410 (98.3)       5,280 (82.4)         No       2,321 (10.7)       1,166 (8.5)       25 (1.7)       1,130 (17.6)         Shortness of breath       Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion       Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)         Headache	No	18,688 (86.6)	12,101 (88.1)	1,328 (92.5)	5,259 (82.0)
No 2,396 (11.1) 954 (7.0) 267 (18.6) 1,175 (18.3) Cough  Yes 19,249 (89.2) 12,559 (91.5) 1,410 (98.3) 5,280 (82.4) No 2,321 (10.7) 1,166 (8.5) 25 (1.7) 1,130 (17.6) Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8) No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2) Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9) No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1) Headache	Sore throat				
Cough  Yes 19,249 (89.2) 12,559 (91.5) 1,410 (98.3) 5,280 (82.4)  No 2,321 (10.7) 1,166 (8.5) 25 (1.7) 1,130 (17.6)  Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8)  No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9)  No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	Yes	19,174 (88.9)	12,771 (93.0)	1,168 (81.3)	5,235 (81.7)
Yes 19,249 (89.2) 12,559 (91.5) 1,410 (98.3) 5,280 (82.4) No 2,321 (10.7) 1,166 (8.5) 25 (1.7) 1,130 (17.6)  Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8) No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9) No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	No	2,396 (11.1)	954 (7.0)	267 (18.6)	1,175 (18.3)
No 2,321 (10.7) 1,166 (8.5) 25 (1.7) 1,130 (17.6)  Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8)  No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9)  No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	Cough				
Shortness of breath  Yes 8,045 (37.3) 5,010 (36.5) 545 (38.0) 2,490 (38.8)  No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9)  No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	Yes	19,249 (89.2)	12,559 (91.5)	1,410 (98.3)	5,280 (82.4)
Yes       8,045 (37.3)       5,010 (36.5)       545 (38.0)       2,490 (38.8)         No       13,525 (62.7)       8,715 (63.5)       890 (62.0)       3,920 (61.2)         Nasal congestion       Yes       17242 (80.0)       11223 (81.8)       1153 (80.3)       4,866 (75.9)         No       4328 (20.1)       2502 (18.2)       282 (19.7)       1,544 (24.1)         Headache	No	2,321 (10.7)	1,166 (8.5)	25 (1.7)	1,130 (17.6)
No 13,525 (62.7) 8,715 (63.5) 890 (62.0) 3,920 (61.2)  Nasal congestion  Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9)  No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1)  Headache	Shortness of breath				
Nasal congestion Yes 17242 (80.0) 11223 (81.8) 1153 (80.3) 4,866 (75.9) No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1) Headache	Yes	8,045 (37.3)	5,010 (36.5)	545 (38.0)	2,490 (38.8)
Yes     17242 (80.0)     11223 (81.8)     1153 (80.3)     4,866 (75.9)       No     4328 (20.1)     2502 (18.2)     282 (19.7)     1,544 (24.1)       Headache	No	13,525 (62.7)	8,715 (63.5)	890 (62.0)	3,920 (61.2)
No 4328 (20.1) 2502 (18.2) 282 (19.7) 1,544 (24.1) Headache	Nasal congestion				
Headache	Yes	17242 (80.0)	11223 (81.8)	1153 (80.3)	4,866 (75.9)
	No	4328 (20.1)	2502 (18.2)	282 (19.7)	1,544 (24.1)
Yes 17,890 (82.9) 1,1571 (84.3) 1,204 (84.0) 5,115 (79.8)	Headache				
	Yes	17,890 (82.9)	1,1571 (84.3)	1,204 (84.0)	5,115 (79.8)

Table 1 Demographic and clinical characteristics of military trainees according to etiology of febrile respiratory illness (2004–2009) (Continued)

No	3680 (17.1)	2154 (15.7)	231 (16.0)	1,295 (20.2)
Conjunctivitis				
Yes	1,901 (8.8)	1,224 (8.9)	76 (5.3)	601 (9.4)
No	19,669 (91.2)	12,501 (91.1)	1,359 (94.7)	5,809 (90.6)
Body aches				
Yes	15,318 (71.0)	9,804 (71.4)	1,073 (74.8)	4,441 (69.3)
No	6,252 (29.0)	3,921 (28.6)	362 (25.2)	1,969 (30.7)
Nausea/vomiting				
Yes	10,757 (49.9)	7,135 (51.9)	701 (48.9)	2,921 (45.6)
No	10,813 (50.1)	6,590 (48.1)	734 (51.1)	3,489 (54.4)
Asthma				
Yes	1,153 (5.3)	670 (4.9)	85 (5.9)	398 (6.2)
No	20,417 (94.7)	13,055 (95.1)	1,350 (94.1)	6,012 (93.8)
Smoker				
Yes	6,942 (32.2)	4,360 (31.8)	406 (28.3)	2,176 (33.9)
No	14,628 (67.8)	9,365 (68.2)	1,029 (71.7)	4,234 (66.1)
Vaccinated (influenza) <sup>d</sup>				
Yes	14,005 (65.0)	8,685 (63.3)	888 (61.9)	4,432 (69.1)
No	7,565 (35.0)	5,040 (36.7)	547 (38.1)	1,978 (30.9)

<sup>&</sup>lt;sup>a</sup>Continuous variable values reported as "mean (standard deviation)" if symmetric variable or "median (min-max range)" if non-symmetric.

Diego (19.0%), Fort Benning (13.3%), Lackland (7.5%), MCRD Parris Island (8.7%), and Cape May (3.2%). Most subjects were febrile (83.0%) and had a cough (89.2%) and/or sore throat (88.9%) because of study inclusion criteria. Adenovirus-confirmed cases had a higher percentage with a sore throat compared with influenza cases (adenovirus = 93%, influenza = 81.3%; P < .0001). Conversely, influenza-positive cases had a higher percentage with a cough compared with adenovirus-positive cases (influenza = 98.3%, adenovirus = 91.5%; P < .0001). Subject characteristics are reported in Table 1.

# Multivariate analysis

Regression modeling revealed associations with laboratory-confirmed adenovirus and clinical predictors (adjusted OR and 95% CI reported): sore throat (OR, 2.94; 95% CI, 2.66–3.25, cough (OR, 2.33; 95% CI, 2.11–2.57), fever (OR, 2.07; 95% CI, 1.90–2.26), nausea/vomiting (OR, 1.19; 95% CI, 1.11–1.27), and nasal congestion (OR, 1.12; 95% CI, 1.03–1.22). Regression modeling of laboratory-confirmed influenza showed significant associations with cough (OR, 13.85; 95% CI, 9.14–20.97), fever (OR, 1.99; 95% CI, 1.66–2.38), acute onset (OR, 1.46; 95% CI, 1.26–1.68), and body

aches (OR, 1.31; 95% CI, 1.13–1.53). Sore throat, nasal congestion, and nausea/vomiting were associated with laboratory-confirmed adenovirus but not with influenza, while acute onset of illness ( $\leq 3$  days) and body aches were associated with laboratory-confirmed influenza but not with adenovirus. Fever and cough were significantly associated with both adenovirus and influenza. Asthma fell out of the model all together.

Analysis of demographic factors revealed interesting results. Female sex was a protective factor for adenovirus infection (OR, 0.72; 95% CI, 0.66–0.80) but was not associated with influenza. Being a smoker before training was protective for both adenovirus and influenza (OR, 0.92; 95% CI, 0.86–0.99) and OR, 0.77; 95% CI, 0.67–0.88, respectively). Adenovirus was seen year-round and associated with all training seasons, with a protective effect seen during the winter season. However, winter training was significantly associated with influenza, with a protective effect seen during other seasons. Distribution of study cases by seasons and years is illustrated in the Figure 1.


Furthermore, influenza was associated with the first 2 weeks of training (OR, 1.82, 95% CI, 1.50–2.21).

<sup>&</sup>lt;sup>b</sup>Missing data due to seasonal vaccine schedule—Total population, n = 6,067; Adenovirus group, n = 3,670; Influenza group, n = 695; Other group, n = 1,702.


All pneumonias were provider diagnosed.

dIndividuals were considered vaccinated if their vaccination date was ≥14 days.

<sup>&</sup>lt;sup>e</sup>p-value determination -  $\chi^2$  was used for categorical variables; Kruskal Wallis test or one-way ANOVA for continuous variables. All variable were significant at P < .0001 except for shortness of breath (P =0.0300), body aches (P = 0.002), and asthma (P = 0.0002).



**Figure 1** Distribution of laboratory-confirmed influenza and adenovirus cases among military basic trainees, 2004–2009. Histogram depicts all laboratory-confirmed influenza and adenovirus cases in the study population, along with those that were negative for influenza and adenovirus ("other" category), by season and year. Percentage of subjects who were influenza positive and adenovirus positive is also depicted.



Training week was converted to a categorical variable for multivariate analysis (reference category = weeks 7+). Winter was used as the reference category for training season.

Adenovirus was associated with weeks 3 and 4 of training (OR, 1.61; 95% CI, 1.47–1.76), these odds increased during training weeks 5 and 6 (OR, 1.91; 95% CI, 1.74–2.10), with no association seen with influenza during training weeks 3–6. Clinical and demographic factors associated with the development of laboratory-confirmed adenovirus and influenza, as determined by multivariate polychotomous logistic regression analysis, are shown in Figures 2 and 3.


Table 2 displays the performance of clinical diagnostic tests constructed from combinations of predictors for adenovirus. The highest specificity (92.4%) and PPV (81.7%) were noted for a combination of four criteria (sore throat, fever, training weeks 3–6, summer season), but the sensitivity was low (19.5%). The combination of three criteria (sore throat, cough, and fever) yielded both high sensitivity (74.4%) and PPV (71.2%) but had marginal specificity (47.3%). Table 3 displays the results of clinical diagnostic tests constructed from combinations of predictors for influenza. The combination of four criteria (cough, training week 0–2, winter season, and fever) had the highest specificity (97.0%) and PPV (39.4%) but had a sensitivity of 26.9%. The combination of two criteria (cough and fever) showed the highest

sensitivity (84.3%), with a specificity of 27.1% and a PPV of 7.6%.

#### **Discussion**

Adenovirus and influenza infections are the leading cause of FRI outbreaks among military trainees at RTCs. This study compared the predictive values of demographic and clinical factors for laboratory-confirmed adenovirus and laboratory-confirmed influenza from 2004 to 2009 among military trainees. The results of this study may help clinicians distinguish an influenza or adenovirus infection from an illness caused by other FRI, based on clinical symptoms and demographic factors. Distinguishing clinical and demographic factors may aid clinicians with differential diagnosis when laboratory confirmation is not available and allow for appropriate dissemination of antiviral medications for influenza.

Few studies have examined factors associated with specific viral pathogens causing FRI among military populations. A study by McNeill and colleagues investigated the clinical presentation of influenza, adenovirus, and other pathogens causing FRI among military members. They found that overall viral pathogens presented as clinically indistinguishable from one another [17]. Conversely,



**Figure 3** Results of multivariate analysis comparing demographic and clinical factors of military trainees with illness due to influenza. Training week was converted to a categorical variable for multivariate analysis (reference category = weeks 7+). Winter was used as the reference category for training season.

Table 2 Clinical diagnostic tests based on main predictor variables associated with adenovirus among military trainees with febrile respiratory illness

Clinical predictor(s)	SN (%) (95% CI)	SP (%) (95% CI)	PPV (%) (95% CI)	NPV (%) (95% CI)
Sore throat	93.0 (92–93)	18.4 (17–19)	66.6 (65–67)	60.2 (58–62)
Cough	91.5 (91–91)	14.7 (13–15)	65.2 (64–65)	49.8 (47–51)
Fever	87.0 (86–87)	23.9 (22–24)	66.7 (65–67)	51.3 (49–52)
Summer	32.8 (32–33)	73.4 (72–74)	68.5 (67–69)	38.3 (37–39)
Training week 5 & 6	30.2 (29–30)	83.5 (82–84)	76.2 (75–77)	40.6 (39–41)
Fall	24.9 (24–25)	78.8 (77–79)	67.3 (65–68)	37.5 (36–38)
Training week 3 & 4	38.8 (38–39)	76.9 (75–77)	74.6 (73–75)	41.8 (41–42)
Training week 3–6	70.0 (69–70)	59.4 (58–60)	75.3 (74–76)	52.9 (51–53)
Spring	22.9 (22–23)	80.5 (79–81)	67.3 (65–68)	37.4 (36–38)
Sore throat + cough	85.3 (84–85)	30.6 (29–31)	68.3 (67–68)	54.4 (52–55)
Sore throat + fever	81.2 (80–81)	36.7 (35–37)	69.2 (68–69)	52.7 (51–54)
Sore throat + cough + fever	74.4 (73–75)	47.3 (46–48)	71.2 (70–71)	51.4 (50–52)
Sore throat + cough + fever + summer	24.2 (23–24)	86.3 (85–87)	75.5 (74–76)	39.4 (38–40)
Sore throat + cough + fever + training week 3-6	52.8 (51–53)	79.0 (78–79)	81.5 (80–82)	48.9 (48–49)
Sore throat + fever + summer	26.7 (25–27)	83.0 (82–83)	73.4 (72–74)	39.3 (38–40)
Sore throat + fever + training week 3–6	56.7 (55–57)	75.4 (74–76)	80.1 (79–80)	49.9 (48–50)
Sore throat + fever + training week 3-6 + summer	19.5 (18–20)	92.4 (91–92)	81.7 (80–82)	39.6 (38–40)

NOTE. Predictor variables were added to diagnostic test based on descending order of significance with outcome variable (influenza) on multivariate logistic regression results. Adenovirus was compared with FRI other (non-adenovirus confirmed, non-influenza confirmed) and influenza confirmed. CI, confidence interval, calculated with binomial expansion; NPV, negative predictive value; PPV, positive predictive value; SN, sensitivity; SP, specificity.

this present study found several clinical symptoms to be independently associated with adenovirus (sore throat, nausea/vomiting, and nasal congestion) and influenza (acute onset and body aches). Cough and fever were associated with both adenovirus and influenza. However, although cough and fever were associated with

both pathogens, recruits with a cough were significantly more likely to be positive for influenza (OR, 13.6; 95% CI, 9.03–20.48) than adenovirus (OR, 2.32; 95% CI, 2.07–2.59). This is consistent with other studies that have reported fever and cough as highly predictive of influenza infections, and with the Centers

Table 3 Clinical diagnostic tests based on main predictor variables associated with influenza among military trainees with febrile respiratory illness

Clinical predictor(s)	SN (%) (95% CI)	SP (%) (95% CI)	PPV (%) (95% CI)	NPV (%) (95% CI)
Cough	98.3 (97–98)	11.4 (10–11)	7.3 (6–7)	98.9 (98–99)
Fever	85.9 (83–87)	17.1 (16–17)	6.9 (6–7)	94.4 (93–95)
Training week 0–2	54.0 (51–56)	84.0 (83–84)	19.4 (18–20)	96.2 (95–96)
Acute onset	73.9 (71–76)	41.9 (41–42)	8.3 (7–8)	95.7 (95–96)
Body aches	74.8 (72–77)	29.3 (28–29)	7.0 (6–7)	94.2 (93–94)
Winter	50.7 (48–53)	77.6 (77–78)	13.9 (12–14)	95.7 (95–95)
Cough + fever	84.3 (82–86)	27.1 (26–27)	7.6 (7–8)	96.0 (95–96)
Cough + training week 0–2	53.4 (50–56)	85.9 (85–86)	21.3 (19–22)	96.3 (96–96)
Cough + training week 0-2 + fever	43.7 (41–46)	89.4 (88–89)	22.7 (21–24)	95.7 (95–95)
Cough + training week 0-2 + fever + acute onset	33.2 (30–35)	93.9 (93–94)	27.9 (25–30)	95.2 (94–95)
Training week 0–2 + winter	9.3 (7–10)	95.4 (95–95)	12.6 (10–14)	93.7 (93–93)
Cough + training week 0-2 + winter	33.9 (31–36)	95.8 (95–96)	36.3 (33–38)	95.3 (95–95)
Cough + training week 0-2 + winter + fever	26.9 (24–29)	97.0 (96–97)	39.4 (36–42)	94.9 (94–95)

NOTE. Predictor variables were added to diagnostic test based on descending order of significance with outcome variable (influenza) on multivariate logistic regression results. Influenza was compared with other FRI (non-adenovirus confirmed, non-influenza confirmed) and adenovirus confirmed. CI, confidence interval, calculated with binomial expansion; NPV, negative predictive value; PPV, positive predictive value; SN, sensitivity; SP, specificity.

for Disease Control and Prevention definition for influenza-like illness [6,18,19].

The clinical presentation of adenovirus illness described in this paper is similar to other military studies [17,20]. A study conducted by Brosch et al. looking at clinical predictors for adenovirus 14 showed that the majority of adenovirus cases had cough and fever [18]. McNeill et al. found similar results [17,20]. Several other studies have seen an association between adenovirus infection and either abdominal pain or nausea [5,17,21], consistent with the present study. A recent study evaluating the clinical presentation of military personnel presenting with FRI found that influenza-positive cases were more likely to present with a runny nose, chills, and ocular symptoms than were other FRI cases, which were more likely to present with a sore throat and nausea/vomiting [8]. Interestingly, our study found sore throat and nausea/vomiting to be solely associated with

In this study, demographic factors associated with adenoviral infections included male sex, smoking, training week (weeks 5 and 6) and training season (spring, summer, and fall months). The protective association seen between smoking and both adenovirus and influenza infections appears counterintuitive. Although the literature is conflicting, a protective effect has previously been seen with adenovirus infections [22]. However, the majority of studies published have shown smoking is a risk factor for FRI [21,23,24]. That said, all military training facilities are smoke free and the protective effect seen among adenovirus-positive individuals may be a result of more frequent adenovirus infections seen among smokers in general, hence a natural immunity may have been present prior to military enlistment [25]. Our results substantiate previous studies that reported adenovirus-associated illness in training weeks 3-6 and the protective effect of female sex [11,12,26,27]. We found that influenza was more likely to occur within the first 2 weeks of training and during the winter season, whereas adenovirus was more likely to occur during weeks 3-6 of training and during the spring, summer, and fall seasons. Training week and seasons are potential tools that clinicians can use to aid in differential diagnosis of FRI among military trainees. Clinical predictors found in this study can aid with quarantine procedures during and FRI outbreak thus reducing the spread of disease and reducing costs to the US government.

# **Conclusions**

After a 12-year absence, second-generation oral vaccines for adenovirus types 4 and 7 resumed distribution at RTCs in October 2011. Since that time, rates of FRI and adenoviral morbidity have decreased substantially.

Although there is hope that the cross-protective effect of the vaccines will be seen among the non-vaccine-targeted adenovirus serotypes, it will be important to track the response of different serotypes to the vaccines. The body of literature could be enhanced by conducting further studies examining clinical and demographic characteristics of adenovirus subtypes causing FRI at RTCs, with a comparative analysis pre- and post-vaccine distribution.

Although our study included a robust sample size and laboratory-confirmed illness, it predominately consisted of young men in a military training environment. The epidemiology and pathogens causing respiratory illness among military recruits is often unique and different from that of the civilian setting. As a result, these finding may not be generalizable to the civilian population. Lastly, clinical predictors of influenza and adenovirus may differ among viral subtypes. Further studies are needed to explore the clinical presentation among subtypes of viral pathogens.

### Competing interests

The authors declare that they have no competing interests.

#### Authors' contributions

DSP participated in the design of the study, coordinated study activities, conducted data analysis, and drafted the manuscript. DF conceived of the study and participated in its design, supervised laboratory reference testing, and participated in manuscript revision. SB participated in the design of the study and manuscript revision. HL participated in the design of the study and assisted with data analysis. AH and SP assisted with data analysis, participated in the design, and assisted in manuscript revision. PB participated in manuscript revision. All authors read and approved the final manuscript.

#### Authors' information

Ms. Padin is a study coordinator and epidemiologist at the Naval Health Research Center (NHRC). Dr. Brodine is a researcher at NHRC, and a professor and Epidemiology Division Head at San Diego State University (SDSU) Graduate School of Public Health (GSPH). Dr. Lemus is an assistant professor at SDSU GSPH. Dr. Blair is department head for the NHRC Operational Infectious Diseases (OID) Department. Dr. Faix is assistant department head for NHRC OID. Mr. Hawksworth is the senior data manager and surveillance study coordinator for NHRC OID. Dr. Putnam is head of the Enteric Disease Surveillance Program for NHRC OID.

#### Acknowledgments

We are grateful to research assistants at the recruit training centers and laboratory staff at the Naval Health Research Center who performed all subject enrollments and testing, without whose support such studies could not be conducted

# Funding

This work was supported by the Armed Forces Health Surveillance Center, Global Emerging Infections Surveillance and Response System (GEIS) operations, under work unit number 60501. The funding organization was not involved in study design, data collection, analysis, interpretation of results, or manuscript writing. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC.1999.0002).

#### Author details

<sup>1</sup>Naval Health Research Center, 140 Sylvester Road, San Diego, CA 92106, USA. <sup>2</sup>Graduate School of Public Health, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, USA.

Received: 13 May 2014 Accepted: 17 October 2014 Published online: 05 December 2014

#### References

- Hilleman MR: Epidemiology of adenovirus respiratory infections in military recruit populations. Ann NY Acad Sci 1957, 67(8):262–272.
- Artenstein AW, Opal JM, Opal SM, Tramont EC, Peter G, Russell PK: History of U.S. military contributions to the study of vaccines against infectious diseases. Mil Med 2005, 170(4 Suppl):3–11.
- Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC: Respiratory diseases among U.S. military personnel: countering emerging threats. Emera Infect Dis 1999, 5(3):379–385.
- Russell KL: Respiratory Infections in Military Recruits. In Textbooks of Military Medicine: Recruit Medicine. Edited by DeKoning Bl. Washington, DC: Bordon Institute; 2006:227–253.
- Puzelli S, Valdarchi C, Ciotti M, Dorrucci M, Farchi F, Babakir-Mina M, Perno CF, Donatelli I, Rezza G: Viral causes of influenza-like illness: insight from a study during the winters 2004–2007. J Med Virol 2009, 81(12):2066–2071.
- Boivin G, Hardy I, Tellier G, Maziade J: Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000, 31(5):1166–1169.
- Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T: Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 2005, 41(8):1198-1200
- Lee VJ, Yap J, Cook AR, Tan CH, Loh JP, Koh WH, Lim EA, Liaw JC, Chew JS, Hossain I, Chan KW, Ting PJ, Ng SH, Gao Q, Kelly PM, Chen MI, Tambyah PA, Tan BH: A clinical diagnostic model for predicting influenza among young adult military personnel with febrile respiratory illness in Singapore. PLoS One 2011, 6(3):e17468.
- Kasper MR, Wierzba TF, Sovann L, Blair PJ, Putnam SD: Evaluation of an influenza-like illness case definition in the diagnosis of influenza among patients with acute febrile illness in Cambodia. BMC Infect Dis 2010, 10:320.
- Gray GC, McCarthy T, Lebeck MG, Schnurr DP, Russell KL, Kajon AE, Landry ML, Leland DS, Storch GA, Ginocchio CC, Robinson CC, Demmler GJ, Saubolle MA, Kehl SC, Selvarangan R, Miller MB, Chappell JD, Zerr DM, Kiska DL, Halstead DC, Capuano AW, Setterquist SF, Chorazy ML, Dawson JD, Erdman DD: Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004–2006. Clin Infect Dis 2007, 45(9):1120–1131.
- Faix DJ, Houng HS, Gaydos JC, Liu SK, Connors JT, Brown X, Asher LV, Vaughn DW, Binn LN: Evaluation of a rapid quantitative diagnostic test for adenovirus type 4. Clin Infect Dis 2004, 38(3):391–397.
- Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, Hansen CJ, Gray GC, Gaydos JC: Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. Vaccine 2006, 24(15):2835–2842.
- Sivan AV, Lee T, Binn LN, Gaydos JC: Adenovirus-associated acute respiratory disease in healthy adolescents and adults: a literature review. Mil Med 2007, 172(11):1198–1203.
- Grayston JT, Woolridge RL, Loosli CG, Gundelfinger BF, Johnston PB, Pierce WE: Adenovirus infections in naval recruits. J Infect Dis 1959, 104(1):61–70.
- van Elden LJ, Nijhuis M, Schipper P, Schuurman R, van Loon AM: Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. J Clin Microbiol 2001, 39(1):196–200.
- Schmidt-Schläpfer G, Liese JG, Porter F, Stojanov S, Just M, Belohradsky BH: Polymerase chain reaction (PCR) compared with conventional identification in culture for detection of *Bordetella pertussis* in 7153 children. Clin Microbiol Infect 1997, 3(4):462–467.
- McNeill KM, Vaughn BL, Brundage MB, Yuanzhang L, Poropatich RK, Gaydos JC: Clinical presentations for influenza and influenza-like illness in young, immunized soldiers. Mil Med 2005, 170(1):94–97.
- Monto A, Gravenstein S, Elliot M, Colopy M, Schweinle J: Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000, 160:3243–3247.
- Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, Sherman SS, Tueller JE, Warkentien T, Sanguineti G, Bavaro M, Hale BR: Clinical and

- epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. *Clin Infect Dis* 2009, **49**(12):1801–1810.
- Brosch L, Tchandja J, Marconi V, Rasnake M, Prakash V, McKnight T, Bunning M: Adenovirus serotype 14 pneumonia at a basic military training site in the United States, spring 2007: a case series. Mil Med 2009, 174(12):1295–1299.
- Centers for Disease Control and Prevention (CDC): Update: swine influenza A (H1N1) infections—California and Texas, April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(16):435–437.
- Ryan MAK, Gray GC, Smith B, McKeehan JA, Hawksworth AW, Malasig MD: Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clin Infect Dis 2002, 34(5):577–582.
- Sanchez JL, Binn LN, Innis BL, Reynolds RD, Lee T, Mitchell-Raymundo F, Craig SC, Marquez JP, Shepherd GA, Polyak CS, Conolly J, Kohlhase KF: Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults. J Med Virol 2001, 65(4):710–718.
- Blake GH, Abell TD, Stanley WG: Cigarette smoking and upper respiratory infection among recruits in basic combat training. Ann Intern Med 1988, 109(3):198–202.
- Tate JE, Bunning ML, Lott L, Lu X, Su J, Metzgar D, Brosch L, Panozzo CA, Marconi VC, Faix DJ, Prill M, Johnson B, Erdman DD, Fonseca V, Anderson LJ, Widdowson MA: Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US Air Force training facility in 2007. J Infect Dis 2009, 199(10):1419–1426.
- Kolavic-Gray SA, Binn LN, Sanchez JL, Cersovsky SB, Polyak CS, Mitchell-Raymundo F, Asher LV, Vaughn DW, Feighner BH, Innis BL: Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis 2002, 35(7):808–818.
- Rosenbaum MJ, Edwards EA, Frank PF, Pierce WE, Crawford YE, Miller LF: Epidemiology and prevention of acute respiratory disease in naval recruits. I. Ten years' experience with microbial agents isolated from naval recruits with acute respiratory disease. Am J Public Health Nations Health 1965, 55:38–46.

#### doi:10.1186/s12879-014-0576-2

Cite this article as: Padin *et al.*: Retrospective analysis of demographic and clinical factors associated with etiology of febrile respiratory illness among US military basic trainees. *BMC Infectious Diseases* 2014 **14**:576.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



# REPORT DOCUMENTATION PAGE

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB Control number. PLEASE DO NOT RETURN YOUR

FORM TO THE ABOVE ADDRESS.		
1. REPORT DATE (DD MM YY) 07 09 12	2. REPORT TYPE Journal	3. DATES COVERED (from – to) November 2004–October 2009
4. TITLE Retrospective Analysis of Etiology of Febrile Respira 6. AUTHORS Padin, Damaris; Faix, Den Hawksworth, Anthony; Put 7. PERFORMING ORGANIZATION Commanding Officer Naval Health Research Ce	Sasic Trainees  5c. Program Element Number: 5d. Project Number: 5e. Task Number:	
140 Sylvester Rd San Diego, CA 92106-352	8. PERFORMING ORGANIZATION REPORT NUMBER	
8. SPONSORING/MONITORING AN Commanding Officer	GENCY NAMES(S) AND ADDRESS(E Chief, Bureau of Me	
Naval Medical Research C 503 Robert Grant Ave	Falls Church, VA 22	
Silver Spring, MD 20910-7	500	11. SPONSOR/MONITOR'S REPORT NUMBER(s)

#### 12. DISTRIBUTION/AVAILABILITY STATEMENT

Approved for public release; distribution is unlimited.

## 13. SUPPLEMENTARY NOTES

BMC Infectious Diseases, 2014, 14, 576-86

#### 14. ABSTRACT

**Background:** Basic trainees are historically vulnerable to outbreaks of febrile respiratory illness (FRI). Adenovirus and influenza are common agents responsible for FRI, presenting with similar clinical symptoms. Identifying factors to differentiate between adenovirus and influenza will improve differential diagnosis and improve troop readiness. **Methods:** Specimens were collected from military trainees meeting FRI case definition (fever ≥ 100.5°F with either cough or sore throat; or provider-diagnosed pneumonia) at eight training centers. PCR and/or cell culture testing for respiratory pathogens were performed. Polychotomous logistic regression was employed to assess the association between factors and FRI outcome. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for combinations of predictors.

**Results:** Among 21,570 FRI cases sampled between 2004 and 2009, 63.6% were confirmed adenovirus cases and 6.65% were confirmed influenza. The best multivariate predictors of adenovirus were sore throat (OR, 2.94; 95% CI, 2.66–3.25), cough (OR, 2.33; 95% CI, 2.11–2.57), and fever (OR, 2.07; 95% CI, 1.90–2.26), with a PPV of 77% ( $p \le .05$ ). A combination of cough, fever, training week 0–2, and acute onset were most predictive of influenza (PPV = 38%;  $p \le .05$ ). **Conclusions:** Specific demographic and clinical factors were associated with influenza and adenovirus among military trainees.

#### 15. SUBJECT TERMS adenovirus, influenza, military trainees, military medicine, diagnosis 16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 18a. NAME OF RESPONSIBLE PERSON **OF ABSTRACT OF PAGES** Commanding Officer a. REPORT D. ABSTRACT c. THIS PAGE **UNCL** 11 **UNCL** UNCL UNCL 18b. TELEPHONE NUMBER (INCLUDING AREA CODE) COMM/DSN: (619) 553-8429